Tibet Weixinkang Medicine Co Ltd Net Assets
Tibet Weixinkang Medicine Co Ltd net assets. Based on the latest financial reports, Tibet Weixinkang Medicine Co Ltd (603676) has net assets worth CN¥1.54 Billion CNY (≈ $225.47 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥1.96 Billion ≈ $287.49 Million USD) and total liabilities (CN¥423.85 Million ≈ $62.02 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Also explore Tibet Weixinkang Medicine Co Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | CN¥1.54 Billion |
| % of Total Assets | 78.43% |
| Annual Growth Rate | 16.04% |
| 5-Year Change | 38.33% |
| 10-Year Change | 221.35% |
| Growth Volatility | 22.95 |
Net Assets of Tibet Weixinkang Medicine Co Ltd (2013–2025)
Net assets of Tibet Weixinkang Medicine Co Ltd from 2013 to 2025. This chart illustrates how Tibet Weixinkang Medicine Co Ltd's net assets have evolved over time, based on quarterly financial data. See 603676 equity financing ratio to measure how much of total assets are equity-financed.
Annual Net Assets for Tibet Weixinkang Medicine Co Ltd (2013–2025)
The table below shows the annual net assets of Tibet Weixinkang Medicine Co Ltd from 2013 to 2025. For live market cap and overall valuation, see Tibet Weixinkang Medicine Co Ltd market cap and net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | CN¥1.48 Billion ≈ $216.04 Million |
+6.56% |
| 2024-12-31 | CN¥1.39 Billion ≈ $202.73 Million |
+3.36% |
| 2023-12-31 | CN¥1.34 Billion ≈ $196.13 Million |
+9.81% |
| 2022-12-31 | CN¥1.22 Billion ≈ $178.61 Million |
+14.37% |
| 2021-12-31 | CN¥1.07 Billion ≈ $156.17 Million |
+8.55% |
| 2020-12-31 | CN¥983.21 Million ≈ $143.87 Million |
+5.72% |
| 2019-12-31 | CN¥930.05 Million ≈ $136.10 Million |
+3.61% |
| 2018-12-31 | CN¥897.64 Million ≈ $131.35 Million |
+4.61% |
| 2017-12-31 | CN¥858.04 Million ≈ $125.56 Million |
+86.77% |
| 2016-12-31 | CN¥459.42 Million ≈ $67.23 Million |
+14.02% |
| 2015-12-31 | CN¥402.93 Million ≈ $58.96 Million |
+40.75% |
| 2014-12-31 | CN¥286.28 Million ≈ $41.89 Million |
+15.54% |
| 2013-12-31 | CN¥247.78 Million ≈ $36.26 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Tibet Weixinkang Medicine Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 207.0% over the analyzed period, indicating profitable operations and earnings retention.
Tibet Weixinkang Medicine Co Ltd Net Assets Breakdown (December 2025)
Tibet Weixinkang Medicine Co Ltd net assets breakdown by equity component as of December 2025.
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | CN¥613.23 Million | 41.54% |
| Other Components | CN¥863.14 Million | 58.46% |
| Total Equity | CN¥1.48 Billion | 100.00% |
Tibet Weixinkang Medicine Co Ltd Competitors by Market Cap
The table below lists competitors of Tibet Weixinkang Medicine Co Ltd ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Inox Green Energy Services Limited
NSE:INOXGREEN
|
$524.77 Million |
|
Zhejiang Starry Pharm Co Ltd
SHG:603520
|
$524.77 Million |
|
Jiangsu Yike Food Group Co.Ltd
SHE:301116
|
$524.94 Million |
|
Shenzhen Prince New Materials Co Ltd
SHE:002735
|
$524.95 Million |
|
Shenzhen Soling Industrial Co Ltd
SHE:002766
|
$524.68 Million |
|
Assure Tech Hangzhou Co Ltd
SHG:688075
|
$524.60 Million |
|
Jiangsu Jiangnan High Polymer Fiber Co Ltd
SHG:600527
|
$524.56 Million |
|
Medprin Regenerative Medical Technologies Co. Ltd.
SHE:301033
|
$524.42 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Tibet Weixinkang Medicine Co Ltd's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 1,385,442,206 to 1,476,367,823, a change of 90,925,617 (6.6%).
- Net income of 232,854,915 contributed positively to equity growth.
- Dividend payments of 163,436,352 reduced retained earnings.
- Other comprehensive income decreased equity by 1,357,957.
- Other factors increased equity by 22,865,012.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | CN¥232.85 Million | +15.77% |
| Dividends Paid | CN¥163.44 Million | -11.07% |
| Other Comprehensive Income | CN¥-1.36 Million | -0.09% |
| Other Changes | CN¥22.87 Million | +1.55% |
| Total Change | CN¥- | 6.56% |
Book Value vs Market Value Analysis
This analysis compares Tibet Weixinkang Medicine Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 2.43x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 6.37x to 2.43x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | CN¥1.29 | CN¥8.24 | x |
| 2014-12-31 | CN¥136.28 | CN¥8.24 | x |
| 2015-12-31 | CN¥2.21 | CN¥8.24 | x |
| 2016-12-31 | CN¥1.28 | CN¥8.24 | x |
| 2017-12-31 | CN¥2.20 | CN¥8.24 | x |
| 2018-12-31 | CN¥2.08 | CN¥8.24 | x |
| 2019-12-31 | CN¥2.17 | CN¥8.24 | x |
| 2020-12-31 | CN¥2.36 | CN¥8.24 | x |
| 2021-12-31 | CN¥2.56 | CN¥8.24 | x |
| 2022-12-31 | CN¥2.83 | CN¥8.24 | x |
| 2023-12-31 | CN¥3.13 | CN¥8.24 | x |
| 2024-12-31 | CN¥3.21 | CN¥8.24 | x |
| 2025-12-31 | CN¥3.39 | CN¥8.24 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Tibet Weixinkang Medicine Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 15.77%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 20.50%
- • Asset Turnover: 0.61x
- • Equity Multiplier: 1.26x
- Recent ROE (15.77%) is below the historical average (17.73%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 35.18% | 24.23% | 1.11x | 1.31x | CN¥59.37 Million |
| 2014 | 37.30% | 27.31% | 1.08x | 1.27x | CN¥78.12 Million |
| 2015 | 28.03% | 25.65% | 0.87x | 1.26x | CN¥72.64 Million |
| 2016 | 25.01% | 26.95% | 0.77x | 1.20x | CN¥68.97 Million |
| 2017 | 11.84% | 24.17% | 0.41x | 1.18x | CN¥15.78 Million |
| 2018 | 8.18% | 9.84% | 0.60x | 1.38x | CN¥-16.33 Million |
| 2019 | 5.99% | 7.51% | 0.57x | 1.40x | CN¥-37.33 Million |
| 2020 | 5.94% | 8.16% | 0.53x | 1.38x | CN¥-39.90 Million |
| 2021 | 8.99% | 9.28% | 0.69x | 1.40x | CN¥-10.82 Million |
| 2022 | 14.50% | 12.65% | 0.84x | 1.36x | CN¥54.90 Million |
| 2023 | 15.97% | 16.18% | 0.74x | 1.33x | CN¥79.98 Million |
| 2024 | 17.77% | 18.93% | 0.70x | 1.34x | CN¥107.62 Million |
| 2025 | 15.77% | 20.50% | 0.61x | 1.26x | CN¥85.22 Million |
Industry Comparison
This section compares Tibet Weixinkang Medicine Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $4,035,280,030
- Average return on equity (ROE) among peers: 6.70%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Tibet Weixinkang Medicine Co Ltd (603676) | CN¥1.54 Billion | 35.18% | 0.28x | $524.71 Million |
| Shenzhen Neptunus Bioengineering Co Ltd (000078) | $6.47 Billion | 9.84% | 3.77x | $485.12 Million |
| Anhui Fengyuan Pharmaceutical Co Ltd (000153) | $775.01 Million | 2.45% | 0.87x | $363.11 Million |
| Shan Dong Dong-E E-Jiao Co Ltd (000423) | $10.74 Billion | 10.72% | 0.24x | $4.79 Billion |
| Livzon Pharmaceutical Group Inc (000513) | $15.79 Billion | 12.81% | 0.52x | $2.70 Billion |
| Wedge Industrial Co Ltd (000534) | $596.67 Million | 0.77% | 0.03x | $1.28 Billion |
| Yunnan Baiyao Group Co Ltd (000538) | $893.64 Million | 25.78% | 0.79x | $14.40 Billion |
| Hainan Haiyao Co Ltd (000566) | $1.59 Billion | 5.90% | 1.18x | $770.77 Million |
| Tus Pharmaceutical Group Co Ltd (000590) | $267.57 Million | 2.03% | 1.53x | $275.43 Million |
| Northeast Pharmaceutical Group Co Ltd (000597) | $1.60 Billion | -10.44% | 3.72x | $925.00 Million |
| Jilin Aodong Pharmaceutical Group Co Ltd (000623) | $1.63 Billion | 7.16% | 0.55x | $3.01 Billion |
About Tibet Weixinkang Medicine Co Ltd
Tibet Weixinkang Medicine Co., Ltd. engages in the research and development, production, and sale of chemical drugs and their bulk drugs in China. It offers APIs; multivitamins and pediatric multivitamins for injections; concentrate of trace elements solution for infusion; compound and pediatric compound amino acid injections; iron sucrose, multiple electrolytes, potassium aspartate and magnesium… Read more